Skip to main content
Average ER Wait Times

Belton Regional Medical Center

-- mins

Centerpoint Medical Center

-- mins

ER of Brookside

-- mins

ER of Olathe (freestanding)

-- mins

ER of Shawnee (freestanding)

-- mins

Lafayette Regional Health Center

-- mins

Lee's Summit Medical Center

-- mins

Menorah Medical Center

-- mins

Overland Park Regional Medical Center

-- mins

Pediatric ER of Overland Park

-- mins

Research Medical Center

-- mins

Clinical Research Trials

The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through the Kansas City Clinical Oncology Program (KCCOP), Sarah Cannon Research Institute, and various pharmaceutical and CRO partners.

CLL38: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) - protocol number UTX-TGR-304.
Facility: Menorah Medical Center, Research Medical Center

CLL39: A Multi-center, OPen-Label Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304.
Facility: Menorah Medical Center, Research Medical Center

CTSU E3A06:

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CTSU NCI 9177:

Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

ECOG-ACRIN E1412:

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

PREAMBLE:

A Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

S1318:

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

​CTSU E1910:

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Alliance A011106:

Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal Women.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 258:

A Phase III, multicenter, randomized, placebo-controlled study of atezolizumab in combination with nab-paclitaxel compared with palcebo with nab-paclitaxel for patients with previously untreated metastatic triple-negative breast cancer.


Facility: Menorah Medical Center, Research Medical Center

BRE273: A randomized, multicenter, phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer.
Facility: Menorah Medical Center, Research Medical Center

BRE279: A Phase I/II, Single Arm, Open-Label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Post-Menopausal Women with HR+, Her2 - Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK4/6 Inhibitor.
Facility: Menorah Medical Center, Research Medical Center

CTSU Alliance A011202:

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CTSU Alliance Z11102:

Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC).


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CTSU NSABP B-51:

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

ECOG-ACRIN E2112:

A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cance


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

NRG-BR003:

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

NSABP B-55:

"A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy"


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S1207:

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (E3 Breast Cancer Study - Evaluating Everolimus with Endocrine Therapy).


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

URCC 10055:

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment, and at Six Month Follow-Up.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

  :  
Facility:  

CTSU Alliance N1048:

PROSPECT: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CTSU E7208:

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GI 189:

A Two Arm Safety Study of Regorafenib before or after SIR-Spheres® Microspheres (90Y) for the Treatment of Patients with Refractory Metastatic Colorectal Cancer and Liver Metastases.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GI 195:

Phase II Study of Carfilzomib for the Treatment of Patients with Advanced Neuroendocrine Cancers​


Facility: Menorah Medical Center, Research Medical Center

GI 201:

A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line treatment of Patients with Metastatic Gastroesophageal Cancer.


Facility: Menorah Medical Center, Research Medical Center

GI222: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5475 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Facility: Menorah Medical Center, Research Medical Center

RTOG 0848:

A Phase IIR and a Phase III Trial Evaluating Both Erlotinib (Ph IIR) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S0820:

A Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Reccurence of High Risk Adenomas and Secon Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

​SWOG S1313:

A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S1216:

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK?700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S1314: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GOG-0213:

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GOG-0237:

Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GOG-0238:

A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cedaranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS).
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

​GOG-0225:

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Alliance A091305:

A Phase 2 Randomized Study Of Efatutazone, An Oral PPAR Agonist, In Combination With Paclitaxel Versus Paclitaxel In Patients With Advanced Anaplastic Thyroid Cancer.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

RTOG 0920:

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CNS25: A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress /Recur After Irradiation with Adjuvant Temozolomide Chemotherapy STELLAR Study.
Facility: Research Medical Center

CTSU Alliance A071101:

A Phase II Randomized Trial Compaing the Efficacy of Heat Shock Protein-Peptide Complex-96 Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

REFMAL365: A Phase Ib Study Evaluating the c-MET inhibitor INC280 in Combination with Bevacizumab in Glioblastoma Multiforme (GBM) patients.
Facility: Research Medical Center

RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer - A Collaborative Study of RTOG and KROG.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Alliance A081105:

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Alliance A151216:

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CALGB 30610:

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CTSU E4512:

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

NRG CC003:

Randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

RTOG 1106:

Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S1400I: A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage iv squamous cell lung cancer and no matching biomarker (lung-map sub-study).
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S1403:

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124).


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

​LUN 288:

A Phase II study of the combination of LY3023414 and Necitumumab after first-line chemotherapy for metastatic squamous non-small cell carcinoma of the lung.


Facility: Menorah Medical Center, Research Medical Center

​RTOG 1306:

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

ECOG-ACRIN EA6141:

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S1013:

A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities.


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

SWOG S1320:

A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma.


Facility: Centerpoint Medical Center

SWOG S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

​Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor - Based Therapy.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center